JonathanDanielMizrahiMD

Oncology • New Orleans, LA

Gastrointestinal Cancer

Medical Oncologist

Join to view full profile

Dr. Mizrahi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mizrahi's full profile

Already have an account?

Office
Ochsner Medical Center
1514 Jefferson Highway
New Orleans, LA 70121

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2014 - 2017
University of Florida College of MedicineClass of 2014
Harvard UniversityA.B., Economics, Cum Laude, 2006 - 2010

Certifications & Licensure

MS State Medical License 2023 - 2025
TX State Medical License 2018 - 2025
AL State Medical License 2023 - 2024
GA State Medical License 2023 - 2024
LA State Medical License 2020 - 2024
MO State Medical License 2016 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation Start of enrollment: 2022 Dec 08
Recruiting
Phase 2
Prebiotics in Rectal Cancer Start of enrollment: 2022 Jul 25
Recruiting
Not Applicable
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study Start of enrollment: 2020 Jan 02
Recruiting
Phase 2
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Start of enrollment: 2020 Jul 01
Recruiting
Phase 3
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors Start of enrollment: 2023 Apr 14
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

33 citations
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Chirayu Mohindroo, Merve Hasanov, Jane E. Rogers, Wenli Dong, Laura R. Prakash
Cancer Medicine. 2021-07-11
4 citations
Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury.
Jonathan D. Mizrahi, Michael J. Overman
Oncotarget. 2018-10-09
511 citations
Pancreatic cancer.
Jonathan D Mizrahi, Rishi Surana, Juan W Valle, Rachna T Shroff
Lancet. 2020-06-27

Press Mentions

Experts Stress Importance of Cancer Prevention and Screening on World Cancer DayFebruary 6th, 2023
Prebiotics in Rectal CancerAugust 25th, 2022